Victory Capital Management Inc. Boosts Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Victory Capital Management Inc. increased its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 59.4% during the third quarter, Holdings Channel.com reports. The firm owned 30,537 shares of the company’s stock after purchasing an additional 11,385 shares during the quarter. Victory Capital Management Inc.’s holdings in Dyne Therapeutics were worth $1,097,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of DYN. State of New Jersey Common Pension Fund D bought a new stake in Dyne Therapeutics during the 3rd quarter worth approximately $1,588,000. Privium Fund Management B.V. increased its stake in shares of Dyne Therapeutics by 7.1% in the third quarter. Privium Fund Management B.V. now owns 15,016 shares of the company’s stock worth $539,000 after purchasing an additional 1,000 shares in the last quarter. Hanseatic Management Services Inc. bought a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at $258,000. Arcadia Investment Management Corp MI lifted its stake in shares of Dyne Therapeutics by 9.8% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 38,614 shares of the company’s stock valued at $1,387,000 after buying an additional 3,439 shares in the last quarter. Finally, US Bancorp DE boosted its holdings in Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after buying an additional 1,212 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DYN has been the topic of a number of recent analyst reports. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Chardan Capital reissued a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Royal Bank of Canada assumed coverage on Dyne Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $45.00 price target for the company. Piper Sandler reiterated an “overweight” rating and set a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Finally, JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $50.82.

Insider Transactions at Dyne Therapeutics

In other news, Director Carlo Incerti sold 16,500 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $28.73, for a total value of $474,045.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jason P. Rhodes sold 782 shares of Dyne Therapeutics stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the transaction, the director now directly owns 15,962 shares of the company’s stock, valued at approximately $528,342.20. This represents a 4.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 176,257 shares of company stock worth $6,193,718. 20.77% of the stock is currently owned by company insiders.

Dyne Therapeutics Stock Down 0.7 %

DYN stock opened at $29.23 on Wednesday. Dyne Therapeutics, Inc. has a 52 week low of $10.12 and a 52 week high of $47.45. The firm has a market capitalization of $2.97 billion, a P/E ratio of -8.16 and a beta of 1.10. The company has a fifty day simple moving average of $32.06 and a two-hundred day simple moving average of $35.40.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.